Chad Gridley, MD
Urology · Smithfield, NCNPI 1396180717
Payments from drug & device makers
Across 38 payments — averaging $89.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- KARL Storz Endoscopy-america$1K
- Teleflex LLC$100
- Avanir Pharmaceuticals, Inc.$48
- Sunovion Pharmaceuticals Inc.$32
- Amneal Pharmaceuticals LLC$25
- plus $94 from 6 others
What the payments were for
- Speaking & faculty fees$241%
- Travel & lodging$1,76152%
- Food & beverage$1,60947%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 17 | $1,733 |
| KARL Storz Endoscopy-america | 5 | $1,362 |
| Teleflex LLC | 1 | $100 |
| Avanir Pharmaceuticals, Inc. | 4 | $48 |
| Sunovion Pharmaceuticals Inc. | 2 | $32 |
| Amneal Pharmaceuticals LLC | 2 | $25 |
| Acorda Therapeutics, Inc | 2 | $24 |
| UCB, Inc. | 1 | $19 |
| EMD Serono, Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $13 |
| Neurelis, Inc. | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEPHROSCOPE MIP M$1,207
- GENERAL BPH$679
- LithoVue$501
- GENERAL KIDNEY STONE DISEASE$122
- Lumenis Pulse 120H$117
- GENERAL - THERAPIES$111
- UroLift System$100
How this compares
$3,394 in reported general payments places this provider in the 50th percentile of 434 urology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 51 | $30,896 |
| Mirabegron ErMirabegron | 12 | $4,549 |
| Finasteride | 170 | $2,080 |
| Tamsulosin Hcl | 107 | $1,259 |
| Silodosin | 21 | $721 |
| Oxybutynin Chloride ErOxybutynin Chloride | 13 | $298 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 14 | $280 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 13 | $86 |
Paid to pharmacies, not to this prescriber.
Other urology in Smithfield
- Robert LippittSmithfield$11.4M
- Daniel GeorgeDurham$17.6M
- Thomas PolascikDurham$4.7M
- Judd MoulDurham$4.1M
- John WrennGreensboro$2.9M
- Michael KennellyCharlotte$1.4M
- John KasparRaleigh$1.1M
- Scott MacdiarmidGreensboro$882K
- Glenn PremingerDurham$736K
- Jonathan HamiltonGreenville$695K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.